Studies in rapidly progressing CNS lymphoma (CNSL) have recently confirmed the excellent diagnostic utility of CXCL13 as well as CXCL9 as predictors of diagnosis, severity of the clinical presentation, and response to therapy. This evidence concerns the gene CXCL9 and primary central nervous system lymphoma.